{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Exposure+Treatment&page=2", "query": { "intervention": "Exposure Treatment", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Exposure+Treatment&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-25T10:58:22.180Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01935713", "title": "Preliminary Investigation of Novel Methods to Reduce Children's Secondhand Smoke Exposure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Secondhand Smoke" ], "interventions": [ { "name": "Nicotine polacrilex", "type": "DRUG" }, { "name": "Electronic Cigarette", "type": "DRUG" }, { "name": "Dissolvable Tobacco Lozenge", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Oklahoma", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 89, "start_date": "2012-04", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2026-04-06", "last_synced_at": "2026-09-25T10:58:22.180Z", "location_count": 1, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT01935713" }, { "nct_id": "NCT07385313", "title": "Combined OFM and Vacuum-assisted Therapy for Expedited Regeneration Over Structures", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Soft Tissue Defects", "Soft Tissue Wounds", "Traumatic Soft Tissue Defect" ], "interventions": [ { "name": "Myriad™ applied in conjunction with NPWT", "type": "DEVICE" }, { "name": "NPWT Alone", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Aroa Biosurgery Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2026-03-31", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-09-25T10:58:22.180Z", "location_count": 2, "location_summary": "Aurora, Colorado • San Antonio, Texas", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07385313" }, { "nct_id": "NCT01042379", "title": "I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms", "Breast Cancer", "Breast Tumors", "Angiosarcoma", "TNBC - Triple-Negative Breast Cancer", "HER2-positive Breast Cancer", "HER2-negative Breast Cancer", "Hormone Receptor Positive Tumor", "Hormone Receptor Negative Tumor", "Early-stage Breast Cancer", "Locally Advanced Breast Cancer" ], "interventions": [ { "name": "Standard Therapy", "type": "DRUG" }, { "name": "AMG 386 with or without Trastuzumab", "type": "DRUG" }, { "name": "AMG 479 (Ganitumab) plus Metformin", "type": "DRUG" }, { "name": "MK-2206 with or without Trastuzumab", "type": "DRUG" }, { "name": "AMG 386 and Trastuzumab", "type": "DRUG" }, { "name": "T-DM1 and Pertuzumab", "type": "DRUG" }, { "name": "Pertuzumab and Trastuzumab", "type": "DRUG" }, { "name": "Ganetespib", "type": "DRUG" }, { "name": "ABT-888", "type": "DRUG" }, { "name": "Neratinib", "type": "DRUG" }, { "name": "PLX3397", "type": "DRUG" }, { "name": "Pembrolizumab - 4 cycle", "type": "DRUG" }, { "name": "Talazoparib plus Irinotecan", "type": "DRUG" }, { "name": "Patritumab and Trastuzumab", "type": "DRUG" }, { "name": "Pembrolizumab - 8 cycle", "type": "DRUG" }, { "name": "SGN-LIV1A", "type": "DRUG" }, { "name": "Durvalumab plus Olaparib", "type": "DRUG" }, { "name": "SD-101 + Pembrolizumab", "type": "DRUG" }, { "name": "Tucatinib plus trastuzumab and pertuzumab", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Cemiplimab plus REGN3767", "type": "DRUG" }, { "name": "Trilaciclib with or without trastuzumab + pertuzumab", "type": "DRUG" }, { "name": "SYD985 ([vic-]trastuzumab duocarmazine)", "type": "DRUG" }, { "name": "Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab", "type": "DRUG" }, { "name": "Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab", "type": "DRUG" }, { "name": "Amcenestrant", "type": "DRUG" }, { "name": "Amcenestrant + Abemaciclib", "type": "DRUG" }, { "name": "Amcenestrant + Letrozole", "type": "DRUG" }, { "name": "ARX788", "type": "DRUG" }, { "name": "ARX788 + Cemiplimab", "type": "DRUG" }, { "name": "VV1 + Cemiplimab", "type": "DRUG" }, { "name": "Datopotamab deruxtecan", "type": "DRUG" }, { "name": "Datopotamab deruxtecan + Durvalumab", "type": "DRUG" }, { "name": "Zanidatamab", "type": "DRUG" }, { "name": "Lasofoxifene", "type": "DRUG" }, { "name": "Z-endoxifen", "type": "DRUG" }, { "name": "ARV-471", "type": "DRUG" }, { "name": "ARV-471 + Letrozole", "type": "DRUG" }, { "name": "ARV-471 + Abemaciclib", "type": "DRUG" }, { "name": "Endoxifen + Abemaciclib", "type": "DRUG" }, { "name": "Rilvegostomig + TDXd", "type": "DRUG" }, { "name": "Dan222 + Niraparib", "type": "DRUG" }, { "name": "Sarilumab + Cemiplimab + Paclitaxel", "type": "DRUG" }, { "name": "GSK 5733584", "type": "DRUG" }, { "name": "GSK 5733584 + Dostarlimab", "type": "DRUG" }, { "name": "Ivonescimab (20mg/kg Q3W)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "QuantumLeap Healthcare Collaborative", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5000, "start_date": "2010-03-01", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-09-25T10:58:22.180Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Davis", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01042379" }, { "nct_id": "NCT03949283", "title": "Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Recurrent Ovarian Carcinoma", "Platinum-resistant Ovarian Cancer" ], "interventions": [ { "name": "ChemoID Assay", "type": "DIAGNOSTIC_TEST" }, { "name": "Standard Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "DRUG" ], "sponsor": "Cordgenics, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 150, "start_date": "2019-07-26", "completion_date": "2024-12-30", "has_results": false, "last_update_posted_date": "2024-08-22", "last_synced_at": "2026-09-25T10:58:22.180Z", "location_count": 8, "location_summary": "Los Angeles, California • Miami, Florida • New Orleans, Louisiana + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT03949283" }, { "nct_id": "NCT01212861", "title": "Surgical Treatment of Refractory Open Angle Glaucoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Open Angle Glaucoma" ], "interventions": [ { "name": "Suprachoroidal Dissection Instrument (SDI)", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "iScience Interventional Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2010-08", "completion_date": "2012-05", "has_results": false, "last_update_posted_date": "2012-09-12", "last_synced_at": "2026-09-25T10:58:22.180Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01212861" }, { "nct_id": "NCT02666859", "title": "Virtual Reality Prosthetic Training and Rehabilitation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Amputation of Upper Limb" ], "interventions": [ { "name": "Virtual Reality", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of South Florida", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 10, "start_date": "2016-01", "completion_date": "2019-06", "has_results": false, "last_update_posted_date": "2019-07-12", "last_synced_at": "2026-09-25T10:58:22.180Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02666859" }, { "nct_id": "NCT04426461", "title": "Approach-Avoidance, Computational Framework for Predicting Behavioral Therapy Outcome (AAC-BeT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anxiety", "Depression" ], "interventions": [ { "name": "Behavioral Activation", "type": "BEHAVIORAL" }, { "name": "Exposure-based therapy", "type": "BEHAVIORAL" }, { "name": "Supportive therapy", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Laureate Institute for Brain Research, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 260, "start_date": "2020-09-11", "completion_date": "2026-04-14", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-09-25T10:58:22.180Z", "location_count": 1, "location_summary": "Tulsa, Oklahoma", "locations": [ { "city": "Tulsa", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT04426461" }, { "nct_id": "NCT02482805", "title": "Hormones and Social Anxiety Disorder Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Social Anxiety Disorder" ], "interventions": [ { "name": "Cognitive Behavioral Therapy", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Jasper A. Smits", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 73, "start_date": "2015-07", "completion_date": "2017-04", "has_results": true, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-09-25T10:58:22.180Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02482805" }, { "nct_id": "NCT04998812", "title": "A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Multiple Sclerosis", "Clinically Isolated Syndrome" ], "interventions": [ { "name": "Ocrelizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "FEMALE", "summary": "18 Years to 40 Years · Female only" }, "enrollment_count": 70, "start_date": "2022-04-13", "completion_date": "2025-07-14", "has_results": true, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-09-25T10:58:22.180Z", "location_count": 4, "location_summary": "San Francisco, California • Aurora, Colorado • Chicago, Illinois + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04998812" }, { "nct_id": "NCT07029919", "title": "Personalized Approach To Habits - Sleep", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Adolescent Behavior", "Sleep Disturbance", "Asthma in Children", "Knowledge, Attitudes, Practice", "Attitude", "Habits" ], "interventions": [ { "name": "PATH-S app", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "KDH Research & Communication", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "14 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "14 Years to 17 Years" }, "enrollment_count": 120, "start_date": "2025-07-09", "completion_date": "2026-02-28", "has_results": false, "last_update_posted_date": "2026-04-27", "last_synced_at": "2026-09-25T10:58:22.180Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07029919" } ] }